Finally, we may have solved the mystery of how former

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone
258

Finally, we may have solved the mystery of how former President Obama managed to drag the U.S. into the Paris Climate Accord – effectively a form of binding international treaty – without the necessary Congressional ratification. < >

Crooked cheating lying racist un American:

539540_mass-shootings-obama-64417-in-2019-file-photo-president-barack-obama-attends-640x430.jpg

According to a lawsuit filed Monday, the Obama administration fudged the issue by misrepresenting U.S. Senate instructions set forth in 1992 to pretend that what was a treaty somehow wasn’t a treaty. The implication is that the Obama administration lied in order to railroad through a policy that it feared might get vetoed by Congress.

The case, brought by the public interest law firm Government Accountability & Oversight, centres on an Obama-era State Department Circular 175 memo.

The suit, on behalf of the nonprofit group Energy Policy Advocates (EPA), seeks records requested in June 2019, including the memorandum setting forth State’s “working law” claiming that the U.S. could enter Paris – what the Obama White House called “the most ambitious climate agreement in history” – without obtaining Senate approval required of treaties.

The complaint notes that EPA has come into possession of a document purporting to be theObama State Department’s “Circular 175” memo, a required legal justification which State has been improperly hiding from the public. GAO’s Chris Horner, co-author of a 2017 paper “TheLegal and Economic Case Against the Paris Treaty”, notes that:

If this document EPA has obtained is in fact the actual Circular 175 memo, it represents a major political and legal scandal with significant implications for U.S. participation in Paris, and the effort to bind the U.S. without following the Constitution.

This memo demonstrates the Obama administration’s unlawful entry into the Paris treaty.

Under the Constitution’s Article II, Section 2, no president can commit the U.S. to treaties without Senate advice and consent.

But on the previous occasion the U.S. was offered the chance to enter an international climate agreement under these Senate ground rules – the 1997 Kyoto Protocol – the Senate did not ratify it.

The Obama administration was anxious to avoid the Paris Climate Accord meeting the same rejection – and so sought ways to disguise the fact that what was billed as “the most ambitious climate change agreement in history” was also a treaty.

It did this, Government Accountability & Oversight’s Chris Horner argues, by sleight of hand:

This 18-page memo bases its argument that Paris need not face Article II, Section 2 “advice and consent” in key part on a gross and material misrepresentation of the history of prior climate agreements supposedly authorizing Pres. Obama’s unilateral “ratification” of Paris. The memo falsely asserts that the U.S. Senate, in ratifying the UN Framework Convention in 1992, limited agreements that “would need to be submitted to the Senate for advise and consent (Exec. Rept. 102-55, p. 14)” to those that claim to have “legally binding targets and timetables”. This is demonstrably false, and likely related to the secrecy with which State has treated this document.

Damningly, on this one point the advocacy-heavy “Memorandum of Law” curiously avoids quoting the cited page 14 of Exec. Rept. 102-55, “Report to Accompany Treaty Doc. 102-38”, which in fact says something very different. There the Senate clearly set forth two, distinct hypothetical agreements requiring Senate approval, one of which is any decision “to adopt targets and timetables” – not just those purporting to be “legally binding” (e.g., Kyoto, Paris).[1]

The mystery since 2015 of how the Obama administration skirted this reality is now solved: the memo legally justifying U.S. participation in the Paris Agreement without Senate approval misrepresents the U.S. Senate position. It did so by sleight-of-hand, in a parenthetical invention:

“‘targets and timetables’ [was] understood in that context to mean legally binding targets”[2].

This is unsupported, and in Rept. 102-55 the Senate used both terms deliberately, to describe two distinct scenarios: first, any decision “to adopt targets and timetables would have to be submitted to the Senate for its advice and consent before the United States could deposit its instruments of ratification for such an agreement”, which of course describes Paris; “further”, any attempt to convert the UNFCCC’s non-binding promise then before the Senate into “legally binding targets and timetables …would alter the ‘shared understanding’ of the Convention between the Senate and the executive branch and would therefore require the Senate’s advice and consent.”

In short, the Obama administration misrepresented the facts to involve the U.S. in Paris, and to avoid a repeat of the Kyoto “accord” which died when the Senate refused to even consider it.

President Trump confirmed last month that the U.S. is definitely pulling out of the Paris Accord. As is so often the way with these arrangements – see also: Brexit – it’s a lot easier to enter them than it is to exit them.

As Daily Caller reports:

Trump can finally make the pullout official Monday. The terms stipulate that a partnering country cannot withdraw within the first three years of submission. Trump can send a letter to the United Nations Monday announcing his intention. It won’t become official until one day after the 2020 election.

Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 146

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 60

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
Strathcona and Greenfire Set Sights on Major Merger

Updated Category News Views 68

Strathcona's Bold Move for Greenfire: A Game Changer? Just this week, Strathcona Resources Ltd. decided to make a big splash in the oil sands space by proposing to acquire Greenfire Resources Ltd. This isn’t your run-of-the-mill grab—it's a strategic tango expected to shift billions and reshape what we know about Canada’s oil sands territory. Unpicking the Deal...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 272

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 354

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 414

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 646

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Cars.com Inducement Awards: New CPO Earns Stock Boost

Updated Category News Views 22

Revving Up With Incentives: A Strategic Move by Cars.com Ever seen a stock maneuver that feels more like a chess play than a plain deal? On November 5, 2026, Cars.com (NYSE: CARS) fired up quite a strategic engine. They handed out a heap of restricted stock units—373,345 to be precise—to Mausam Bhatt, freshly minted as their Chief Product Officer. This isn't just your...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 586

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading

Top 5 Most Recently Viewed Articles

Spring Health Launches Initiative for Mental Health Relief

Updated Category News Views 472

Spring Health's Commitment to Mental Health Support In response to the recent devastation from the wildfires, Spring Health has announced a significant initiative aimed at providing mental health resources to those in distress. The company has committed $500,000 to launch a new Wildfire Mental Health Support Program aimed at individuals and families impacted by these...

Continue Reading
Serina Therapeutics Showcases Innovations at Global Conference

Updated Category News Views 263

Serina Therapeutics Takes the Stage at Major Investment Event Serina Therapeutics, Inc., also known as Serina (NYSE American: SER), is set to make an impactful presentation at the H.C. Wainwright 27th Annual Global Investment Conference. This prestigious event unfolds in New York City, where Steve Ledger, the Chief Executive Officer of Serina, will take the spotlight at...

Continue Reading
Patrick Industries Faces Scrutiny Amid Merger Plans

Updated Category News Views 48

Cracks in the Merger Deal? Nobody likes it when a seemingly routine merger suddenly faces the magnifying glass of a class action attorney. But that's where we are with Patrick Industries (NASDAQ: PATK), folks. Juan Monteverde, the big hitter from Monteverde & Associates, is eyeing this one closely. This New York-based firm, perched in the legendary Empire State Building...

Continue Reading
Revolutionary Arab Human Pangenome: Advancing Genomic Equity

Updated Category News Views 124

Groundbreaking Achievement in Genomics PacBio, a renowned leader in sequencing technology, has made a substantial contribution to global genomics with the announcement of the first Arab human pangenome. This historic achievement is powered by their innovative HiFi long-read sequencing technology, showcasing the potential of genomic science to progress health equality...

Continue Reading
RCI Hospitality Secures Significant Legal Representation Ahead of Deadline

Updated Category News Views 226

Introduction to RCI Hospitality Holdings, Inc. RCI Hospitality Holdings, Inc. (NASDAQ: RICK) is known for its diverse portfolio in the hospitality sector. With establishments across the country, RCI focuses on providing entertainment and dining experiences through various brands. As an investor in RCI Hospitality, it’s essential to stay informed about recent legal...

Continue Reading